Cargando…

TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy

Tet methylcytosine dioxygenase 2 (TET2) is one of the most frequently mutated genes in myelodysplastic syndrome (MDS). TET2 is known to involve a demethylation process, and the loss of TET2 is thought to cause DNA hypermethylation. Loss of TET2 function is known to be caused by genetic mutations and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yun, Jina, Ji, Young Sok, Jang, Geum Ha, Lim, Sung Hee, Kim, Se Hyung, Kim, Chan Kyu, Bae, Sang Byung, Won, Jong Ho, Park, Seong Kyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929064/ https://www.ncbi.nlm.nih.gov/pubmed/34449560 http://dx.doi.org/10.3390/cimb43020065

Ejemplares similares

Clinical Experience of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients Aged 60 Years and Older in South Korea
por: Ji, Young Sok, et al.
Publicado: (2023)

Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents
por: Kang, Ka-Won, et al.
Publicado: (2020)

Is Treosulfan-Based Conditioning Attractive as a Reduced-Intensity Conditioning Regimen in Korea?
por: Kim, Se Hyung, et al.
Publicado: (2023)

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome
por: Jung, Seung-Hyun, et al.
Publicado: (2016)

No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
por: Sohn, Sang Kyun, et al.
Publicado: (2018)

Low-level somatic JAK2 V617F mutation in myelodysplastic/ myeloproliferative neoplasm with ring sideroblasts, and thrombocytosis with co-mutated SF3B1 and CALR
por: Ji, Young Sok, et al.
Publicado: (2022)

Aberrant Expression of TET2 Accounts for DNA Hypomethylation in Varicocele
por: Taghian Dinani, Hengameh, et al.
Publicado: (2023)

A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors
por: Loriot, Axelle, et al.
Publicado: (2014)

Hypomethylation of MIR‐378 5’‐flanking region predicts poor survival in young patients with myelodysplastic syndrome
por: Wu, De‐hong, et al.
Publicado: (2019)

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
por: Lasho, Terra L., et al.
Publicado: (2018)

Management of myelodysplastic syndromes after failure of response to hypomethylating agents
por: Gil-Perez, Angela, et al.
Publicado: (2019)

The role of TET2-mediated ROBO4 hypomethylation in the development of diabetic retinopathy
por: Zhao, Liangliang, et al.
Publicado: (2023)

Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
por: Ji, Young Sok, et al.
Publicado: (2016)

Identification of radiation-induced aberrant hypomethylation in colon cancer
por: Bae, Jin-Han, et al.
Publicado: (2015)

Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes
por: Kim, Yundeok, et al.
Publicado: (2014)

Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
por: Lim, Sung Hee, et al.
Publicado: (2021)

Challenges to be addressed in management of patients with sinusoidal obstruction syndrome after hematopoietic cell transplantation
por: Park, Seong Kyu, et al.
Publicado: (2022)

Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020
Publicado: (2021)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

TET1-mediated DNA hypomethylation regulates the expression of MUC4 in lung cancer
por: Yokoyama, Seiya, et al.
Publicado: (2017)

Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine
por: Lim, Sung-Hee, et al.
Publicado: (2021)

Pathophysiological Role of Hormones and Cytokines in Cancer Cachexia
por: Kim, Hyun Jung, et al.
Publicado: (2012)

Safety and Effectiveness of Central Venous Catheterization in Patients with Cancer: Prospective Observational Study
por: Kim, Hyun Jung, et al.
Publicado: (2010)

A controversial conclusion regarding primary extranodal diffuse large B-cell lymphoma
por: Park, Seong Kyu, et al.
Publicado: (2011)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome
por: Zhou, Qing-Bing, et al.
Publicado: (2020)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes
por: Abbas, Hussein A., et al.
Publicado: (2021)

Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome
por: Grimm, Juliane, et al.
Publicado: (2022)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Decrease of 5hmC in gastric cancers is associated with TET1 silencing due to with DNA methylation and bivalent histone marks at TET1 CpG island 3′-shore
por: Park, Jong-Lyul, et al.
Publicado: (2015)

Tet1 regulates epigenetic remodeling of the pericentromeric heterochromatin and chromocenter organization in DNA hypomethylated cells
por: Hagihara, Yota, et al.
Publicado: (2021)

Eight-Month Follow-up After the Third Dose of BNT162b2 Vaccine in Healthcare Workers: The Question of a Fourth Dose
por: Lim, Sung Hee, et al.
Publicado: (2023)

Is immunological recovery clinically relevant at 100 days after allogeneic transplantation?
por: Park, Jin, et al.
Publicado: (2020)

Tousled-like kinase 1 is a negative regulator of core transcription factors in murine embryonic stem cells
por: Lee, Jina, et al.
Publicado: (2018)

Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders
por: Muto, Tomoya, et al.
Publicado: (2013)

Prognostic role of TET2 deficiency in myelodysplastic syndromes: A meta-analysis
por: Lin, Yun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5bn12hg2chmkfnc6sbmhsmllka